Latest news with #NTTDATA
Globe and Mail
6 days ago
- Business
- Globe and Mail
AspireHR Named NTT DATA Business Solutions' Partner of the Year
Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Dallas, TX – [Date] — AspireHR, a leading provider of HCM and SAP solutions, is proud to announce it has been recognized as Partner of the Year by NTT DATA Business Solutions, a global leader in IT services and consulting. This prestigious accolade highlights AspireHR's exceptional contributions, innovation, and collaboration in delivering transformative human capital management solutions that drive business value for clients. The Partner of the Year award honors AspireHR's outstanding performance in joint customer success, solution development, and alignment with NTT DATA Business Solutions' strategic goals throughout the past year. AspireHR's deep SAP expertise, dedication to client outcomes, and agile project delivery have consistently elevated the customer experience and delivered measurable results across industries. 'We are incredibly honored to be named Partner of the Year by NTT DATA Business Solutions,' said Melissa Hillesheim, CEO & Executive Chairwoman of AspireHR. 'This recognition reflects the strength of our partnership and our shared commitment to innovation, excellence, and empowering our clients through cutting-edge SAP and HCM solutions. We look forward to continued collaboration and success in the years ahead.' 'AspireHR has demonstrated what a truly strategic partner looks like,' said Peter Burns, SVP & Chief Revenue Officer United States at NTT DATA Business Solutions. 'Their deep domain expertise, consistent execution, and client-first approach have made a significant impact across multiple engagements. We're proud to recognize AspireHR's achievements with this well-deserved award.' The award was presented during NTT DATA Business Solutions' annual partner summit, which brings together top partners and industry leaders to celebrate innovation, collaboration, and digital transformation success stories from around the globe. As a long-standing partner with a proven track record, AspireHR continues to deliver excellence across SAP SuccessFactors implementations, cloud migrations, and managed services, helping organizations reimagine their workforce strategies and achieve sustainable growth. About AspireHR AspireHR is a premier provider of human capital management (HCM) solutions, specializing in SAP SuccessFactors, SAP HCM, and cloud transformation services. With a client-focused approach and decades of deep HR technology expertise, AspireHR helps organizations maximize the value of their HR systems to achieve business goals faster and more efficiently. Learn more at About NTT DATA Business Solutions NTT DATA Business Solutions is a leading global IT service provider focused on SAP with a powerful ecosystem of partners. With more than 35 years of in-depth experience, we enable companies worldwide to become Intelligent Enterprises. We deliver end-to-end solutions that accelerate sustainable growth and success – from strategic consulting and implementation to managed services and beyond. As a global strategic SAP partner, we drive innovation and leverage the latest technologies to support our customers individually and across all industries. Our more than 16,000 dedicated employees in over 30 countries work passionately every day to make it happen. NTT DATA Business Solutions is part of NTT DATA, a $30+ billion trusted global innovator of business and technology services headquartered in Tokyo. As One NTT DATA we serve 75% of the Fortune Global 100 and are committed to helping customers innovate, optimize and transform for long-term success. NTT DATA is part of NTT Group. Media Contacts: Kelly Sotelo Marketing Manager AspireHR, LLC Email: ksotelo@
Time of India
7 days ago
- Health
- Time of India
Royal Marsden, NTT DATA and CARPL.ai partner to launch AI-Powered Radiology service
London: The Royal Marsden NHS Foundation Trust has partnered with NTT DATA and to develop an AI-powered radiology analysis service aimed at advancing cancer research . The service will support the development and evaluation of artificial intelligence (AI) models in medical imaging, with the goal of improving diagnostic accuracy and patient outcomes . Funded by a three-year grant from the National Institute for Health and Care Research (NIHR), the service will be used in research at The Royal Marsden and the Institute of Cancer Research (ICR), including collaborative projects. Areas of focus include cancers such as sarcoma, lung, breast, brain, and prostate, with the aim of improving cancer evaluation and enabling more targeted treatments. The service runs on an MLOps clinical imaging system built and operated by NTT DATA. It includes high-performance Dell servers and GPU processing capabilities managed through which hosts a wide range of radiology AI models. NTT DATA is also providing consulting services to support testing and evaluation of emerging AI tools in real clinical settings. It is indicated that once the service becomes operational, research teams at The Royal Marsden will use it to assess a variety of AI models across different cancer types. The studies are expected to provide data on how AI tools may contribute to clinical decision-making and inform future diagnostic and treatment approaches. The service includes tools that allow researchers to observe model performance over time, helping to streamline the development and evaluation process. NTT DATA will continue its collaboration with The Royal Marsden to support ongoing research activities.
Business Upturn
7 days ago
- Health
- Business Upturn
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
London, United Kingdom: This partnership launches a large-scale, AI-powered service designed to accelerate cancer detection and treatment using medical imaging in the UK's National Health Service (NHS) The Royal Marsden NHS Foundation Trust is ranked among world's top cancer research centers Marks a milestone in the application of artificial intelligence for cancer research and clinical innovation The Royal Marsden NHS Foundation Trust , a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA , a global leader in digital business and technology services, and , a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Professor Mike Lewis, NIHR Scientific Director for Innovation, said: 'Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. 'This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Wire
7 days ago
- Business
- Business Wire
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
LONDON--(BUSINESS WIRE)-- The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Professor Mike Lewis, NIHR Scientific Director for Innovation, said: "Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. "This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual.
Zawya
7 days ago
- Health
- Zawya
World-leading cancer center, The Royal Marsden NHS Foundation Trust, using AI to push boundaries of cancer research
This partnership launches a large-scale, AI-powered service designed to accelerate cancer detection and treatment using medical imaging in the UK's National Health Service (NHS) The Royal Marsden NHS Foundation Trust is ranked among world's top cancer research centers Marks a milestone in the application of artificial intelligence for cancer research and clinical innovation Dubai, UAE/ London, UK – The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Professor Mike Lewis, NIHR Scientific Director for Innovation, said: "Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. "This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness, The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across northwest and southwest London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual.
